Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar

被引：0
|
作者：
Greenberg, B. M. [1 ]
de Seze, J. [2 ]
Saiz, A. [3 ,4 ]
Yamamura, T. [5 ]
Yeaman, M. [6 ]
Marcillat, C. [7 ]
Kou, X. [7 ]
Weber, K. [7 ]
Blondeau, K. [7 ]
Weinshenker, B. G. [8 ]
Patti, F. [9 ,10 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Hop Hautepierre, Strasbourg, France
[3] Hosp Clin Barcelona, Serv Neurol, Barcelona, Spain
[4] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[5] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo, Japan
[6] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Mayo Clin, Rochester, MN USA
[9] Univ Catania, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Catania, Italy
[10] Multiple Sclerosis Ctr AOU Policlin G Rodolico Sa, Catania, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P023
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [41] LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A 22 MONTH, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Cucchiaro, J.
    Silva, R.
    Hsu, J.
    Pikalov, A.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [42] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [43] Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    MOVEMENT DISORDERS, 2017, 32
  • [44] Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
    Goemans, Nathalie M.
    Tulinius, Mar
    van den Hauwe, Marleen
    Kroksmark, Anna-Karin
    Buyse, Gunnar
    Wilson, Rosamund J.
    van Deutekom, Judith C.
    de Kimpe, Sjef J.
    Lourbakos, Afrodite
    Campion, Giles
    PLOS ONE, 2016, 11 (09):
  • [45] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [46] LONG-TERM EFFICACY OF LANADELUMAB: INTERIM RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Cicardi, M.
    Hao, J.
    Lu, P.
    Li, H.
    Manning, M.
    Bernstein, J.
    Busse, P.
    Tachdjian, R.
    Gower, R.
    Wedner, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S31
  • [47] Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
    Barratt, Jonathan
    Barbour, Sean
    Brenner, Robert
    Cooper, Kerry
    Wei, Xuelian
    Eren, Necmi
    Floege, Juergen
    Jha, Vivekanand
    Kim, Sung Gyun
    Maes, Bart
    Phoon, Richard K. S.
    Singh, Harmeet
    Tesar, Vladimir
    Lafayette, Richard
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024,
  • [48] Safety of satralizumab based on pooled data from phase 3 studies in patients with neuromyelitis optica spectrum disorder
    Greenberg, B.
    De Seze, J.
    Fox, E.
    Saiz, A.
    Yamamura, T.
    Yeaman, M.
    Marcillat, C.
    Kou, X.
    Weber, K.
    Blondeau, K.
    Weinshenker, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 477 - 478
  • [49] Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon
    Traboulsee, Anthony
    Kleiter, Ingo
    Palace, Jacqueline
    Fujihara, Kazuo
    Saiz, Albert
    Vodopivec, Ivana
    Klingelschmitt, Gaelle
    Marcillat, Carole
    Bennett, Jeffrey
    NEUROLOGY, 2023, 100 (17)
  • [50] Long-term efficacy and safety of eculizumab monotherapy in AQP4+neuromyelitis optica spectrum disorder
    Pittock, Sean
    Fujihara, Kazuo
    Palace, Jacqueline
    Berthele, Achim
    Kim, Ho Jin
    Guevara, Celia Oreja
    Nakashima, Ichiro
    Levy, Michael
    Shang, Shulian
    Yountz, Marcus
    Miller, Larisa
    Armstrong, Roisin
    Wingerchuk, Dean
    NEUROLOGY, 2021, 96 (15)
12345